Flunisolide Spray Rx
Generic Name and Formulations:
Flunisolide 25mcg/spray; nasal soln.
Various generic manufacturers
Indications for Flunisolide Spray:
Seasonal or perennial rhinitis.
≥15yrs: Initially 2 sprays in each nostril twice daily; max 8 sprays/nostril per day.
<6yrs: not recommended. 6–14yrs: Initially 1 spray in each nostril 3 times daily or 2 sprays twice daily; max 4 sprays/nostril per day.
Untreated nasal infections.
Maintain regular regimen. Respiratory tract tuberculosis. Infections (eg, ocular herpes simplex). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. Reduce dose as condition improves. May use nasal decongestants if needed. Discontinue if no effect after 3 wks. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, depression). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), and candida infection or other nasal mucosal changes. Avoid eyes. Pregnancy (Cat.C). Nursing mothers.
Nasal discomfort, congestion, sneezing, epistaxis, lacrimation, sore throat, nausea, headache, loss of taste and smell, septal perforation, hypercorticism, fungal overgrowth, impaired wound healing, glaucoma, reduced growth velocity in children.
Formerly known under the brand names Nasalide, Nasarel.
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking